People
Daniel O’Day took over the reins of Gilead Sciences in March and has been building his team of lieutenants.
Arie Belldegrun, founder and former chair, president and chief executive officer of Kite Pharma, has teamed up with real estate developer Tishman Speyer to launch a biotech-focused real estate company, Breakthrough Properties.
Susan Hickman, Ph.D., has been selected to lead the Indiana University Center for Aging Research at the Regenstrief Institute.
Four years ago, Takeda Pharmaceutical Company and The Center for iPS Cell Research and Application (CiRA) at Kyoto University established a 10-year joint research program. Today, the organizations made an announcement.
In November 2018, Chinese researcher He Jiankui announced he had used CRISPR gene editing to modify the CCR5 genes in the embryos of seven Chinese couples. This was met by widespread condemnation, investigations and a call for a global moratorium against that type of research.
Board appointment will help guide target identification and drug discovery
According to reports, Novartis veteran Jonathan Symonds is likely to be named the next chairman of the board.
At Kite, Shaw will focus on turning around the company’s flagship CAR-T treatment Yescarta, as well as focus on the development of other cancer-targeting cell therapies.
With a clear vision in mind Iperion Life Sciences Consultancy has taken the next step in realizing her mission.
Biotech and pharma companies strengthen their leadership teams with new appointments.
PRESS RELEASES